Carcinogenicity of lipid-lowering drugs

T. B. Newman and S. B. Hulley
Department of Laboratory Medicine, School of Medicine, University of California, San Francisco, USA.

OBJECTIVE--To review the findings and implications of studies of rodent carcinogenicity of lipid-lowering drugs. DATA SOURCES--Summaries of carcinogenicity studies published in the 1992 and 1994 Physicians' Desk Reference (PDR), additional information obtained from the US Food and Drug Administration, and published articles identified by computer searching, bibliographies, and consultation with experts. STUDY SAMPLE--We tabulated rodent carcinogenicity data from the 1994 PDR for all drugs listed as "hypolipidemics." For comparison, we selected a stratified random sample of antihypertensive drugs. We also reviewed methods and interpretation of carcinogenicity studies in rodents and results of clinical trials in humans. DATA SYNTHESIS--All members of the two most popular classes of lipid-lowering drugs (the fibrates and the statins) cause cancer in rodents, in some cases at levels of animal exposure close to those prescribed to humans. In contrast, few of the antihypertensive drugs have been found to be carcinogenic in rodents. Evidence of carcinogenicity of lipid-lowering drugs from clinical trials in humans is inconclusive because of inconsistent results and insufficient duration of follow-up. CONCLUSIONS--Extrapolation of this evidence of carcinogenesis from rodents to humans is an uncertain process. Longer-term clinical trials and careful postmarketing surveillance during the next several decades are needed to determine whether cholesterol-lowering drugs cause cancer in humans. In the meantime, the results of experiments in animals and humans suggest that lipid-lowering drug treatment, especially with the fibrates and statins, should be avoided except in patients at high short-term risk of coronary heart disease.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Role of Statin Drugs in the Management of the Peripheral Vascular Patient
Samson
VASC ENDOVASCULAR SURG 2008;42:352-366.
ABSTRACT  

Use of Common Medications and Breast Cancer Risk
Moysich et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:1564-1595.
ABSTRACT | FULL TEXT  

Cholesterol-Lowering Drugs and Prostate Cancer Risk: A Population-based Case-Control Study
Murtola et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:2226-2232.
ABSTRACT | FULL TEXT  

Sequence Variation in Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease Gene, Low LDL Cholesterol, and Cancer Incidence
Folsom et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:2455-2458.
ABSTRACT | FULL TEXT  

Mouse Liver Effects of Cyproconazole, a Triazole Fungicide: Role of the Constitutive Androstane Receptor
Peffer et al.
Toxicol Sci 2007;99:315-325.
ABSTRACT | FULL TEXT  

The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points
Lai and Yuen
ANN INTERN MED 2007;147:58-61.
ABSTRACT | FULL TEXT  

Statins Reduce the Risk of Lung Cancer in Humans: A Large Case-Control Study of US Veterans
Khurana et al.
Chest 2007;131:1282-1288.
ABSTRACT | FULL TEXT  

Statin Use and Breast Cancer Risk in a Large Population-Based Setting
Boudreau et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:416-421.
ABSTRACT | FULL TEXT  

Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly
Setoguchi et al.
Circulation 2007;115:27-33.
ABSTRACT | FULL TEXT  

Statins, Fibrates, and Melanoma Risk: a Systematic Review and Meta-analysis.
Freeman et al.
JNCI J Natl Cancer Inst 2006;98:1538-1546.
ABSTRACT | FULL TEXT  

Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials
Bonovas et al.
JCO 2006;24:4808-4817.
ABSTRACT | FULL TEXT  

Long term safety of statins should be monitored
Haas et al.
BMJ 2006;333:656-656.
FULL TEXT  

Should we lower cholesterol as much as possible?
Ravnskov et al.
BMJ 2006;332:1330-1332.
FULL TEXT  

Statin Use and Risk of Lymphoid Neoplasms: Results from the European Case-Control Study EPILYMPH.
Fortuny et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:921-925.
ABSTRACT | FULL TEXT  

In Reply
Bonovas et al.
JCO 2006;24:2130-2131.
FULL TEXT  

In Reply
Bonovas et al.
JCO 2006;24:2127-2128.
FULL TEXT  

Obesity, Peroxisome Proliferator-Activated Receptor, and Atherosclerosis in Type 2 Diabetes
Blaschke et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:28-40.
ABSTRACT | FULL TEXT  

Can Statin Therapy Reduce the Risk of Breast Cancer?
Vogel
JCO 2005;23:8553-8555.
FULL TEXT  

Use of Statins and Breast Cancer: A Meta-Analysis of Seven Randomized Clinical Trials and Nine Observational Studies
Bonovas et al.
JCO 2005;23:8606-8612.
ABSTRACT | FULL TEXT  

Serum Lipids, Lipid-Lowering Drugs, and the Risk of Breast Cancer
Eliassen et al.
Arch Intern Med 2005;165:2264-2271.
ABSTRACT | FULL TEXT  

Thiamethoxam Induced Mouse Liver Tumors and Their Relevance to Humans: Part 1: Mode of Action Studies in the Mouse
Green et al.
Toxicol Sci 2005;86:36-47.
ABSTRACT | FULL TEXT  

Cholesterol and the Aged: ... and the Beat Goes On
Wilson
J. Gerontol. A Biol. Sci. Med. Sci. 2005;60:600-602.
FULL TEXT  

Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: A meta-analysis of randomized controlled trials
Birjmohun et al.
J Am Coll Cardiol 2005;45:185-197.
ABSTRACT | FULL TEXT  

If It's Not Worth Doing, It's Not Worth Doing Well
Newman
Pediatrics 2005;115:196-196.
FULL TEXT  

The Risk of Cancer in Users of Statins
Graaf et al.
JCO 2004;22:2388-2394.
ABSTRACT | FULL TEXT  

The Toxicology of HMG--CoA Reductase Inhibitors: Prediction of Human Risk
MacDonald and Halleck
Toxicol Pathol 2004;32:26-41.
ABSTRACT  

Lipid-Lowering Therapy and Risk of Coronary Events
Taylor
JAMA 2003;289:2070-2070.
FULL TEXT  

Statin effects beyond lipid lowering--are they clinically relevant?
Bonetti et al.
Eur Heart J 2003;24:225-248.
FULL TEXT  

The Statins as Anticancer Agents
Chan et al.
Clin. Cancer Res. 2003;9:10-19.
ABSTRACT | FULL TEXT  

Low-density lipoprotein lowering therapy: an analysis of the options
Sacks
J Am Coll Cardiol 2002;40:2135-2138.
FULL TEXT  

Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS)
Herrington et al.
Circulation 2002;105:2962-2967.
ABSTRACT | FULL TEXT  

Safety and Tolerability of Pravastatin in Long-Term Clinical Trials: Prospective Pravastatin Pooling (PPP) Project
Pfeffer et al.
Circulation 2002;105:2341-2346.
ABSTRACT | FULL TEXT  

Statins as the new aspirin
Ravnskov and Anton
BMJ 2002;324:789-789.
FULL TEXT  

Cholesterol Guidelines Debate
Gidding; et al.
Pediatrics 2001;107:1229-1230.
FULL TEXT  

Phthalates Rapidly Increase Production of Reactive Oxygen Species in Vivo: Role of Kupffer Cells
Rusyn et al.
Mol. Pharmacol. 2001;59:744-750.
ABSTRACT | FULL TEXT  

Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials
Muldoon et al.
BMJ 2001;322:11-15.
ABSTRACT | FULL TEXT  

Garlic for Treating Hypercholesterolemia: A Meta-Analysis of Randomized Clinical Trials
Stevinson et al.
ANN INTERN MED 2000;133:420-429.
ABSTRACT | FULL TEXT  

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of Cancer: A Nested Case-Control Study
Blais et al.
Arch Intern Med 2000;160:2363-2368.
ABSTRACT | FULL TEXT  

Cholesterol Screening in Children and Adolescents
Newman and MD
Pediatrics 2000;105:637-638.
FULL TEXT  

The Role of Dietary Fat in Child Nutrition and Development: Summary of an ASNS Workshop
Milner and Allison
J. Nutr. 1999;129:2094-2105.
FULL TEXT  

Amlodipine Releases Nitric Oxide From Canine Coronary Microvessels: An Unexpected Mechanism of Action of a Calcium Channel–Blocking Agent
Dhein and Salameh
Circulation 1999;100:1011-1015.
FULL TEXT  

Very-Low-Fat Diets • Response
Barnard et al.
Circulation 1999;100 :1011-1015.
FULL TEXT  

Isolation and identification of novel metabolites of gemfibrozil in rat urine
Thomas et al.
Drug Metab. Dispos. 1999;27:147-157.
ABSTRACT | FULL TEXT  

Intensive Lifestyle Changes for Reversal of Coronary Heart Disease
Ornish et al.
JAMA 1998;280:2001-2007.
ABSTRACT | FULL TEXT  

Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels et al.
Circulation 1998;98:2088-2093.
ABSTRACT | FULL TEXT  

Treating Hyperlipidemia for the Primary Prevention of Coronary Disease: Are Higher Dosages of Lovastatin Cost-effective?
Perreault et al.
Arch Intern Med 1998;158:375-381.
ABSTRACT | FULL TEXT  

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks et al.
NEJM 1996;335:1001-1009.
ABSTRACT | FULL TEXT  

ARE LIPID-LOWERING DRUGS CARCINOGENS?
JWatch General 1996;1996:3-3.
FULL TEXT  

Atherosclerosis and Risk Factor Modification: Does It Really Make a Difference?
Corson et al.
PERSPECT VASC SURG ENDOVASC THER 1996;9:75-94.